Suchergebnisse - "Newell-Price, John"

PubPharm (10)

1

Long-term outcomes of osilodrostat in Cushing's disease : LINC 3 study extension

enthalten in: European journal of endocrinology | 2022

von Fleseriu, M. | Newell-Price, J. | Pivonello, R. | +12

2

Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia

enthalten in: The Journal of clinical endocrinology and metabolism | 2021

von Merke, D. | Mallappa, A. | Arlt, W. | +14

3

Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a double-blind, randomised withdrawal phase

enthalten in: The lancet. Diabetes & endocrinology | 2020

von Pivonello, R. | Fleseriu, M. | Newell-Price, J. | +15

ErratumIn: Lancet Diabetes Endocrinol. 2020 Aug 5;:. - PMID 32768393

4

Outcomes of Patients with Nelson's Syndrome after Primary Treatment : A Multicenter Study from 13 UK Pituitary Centers

enthalten in: The Journal of clinical endocrinology and metabolism | 2020

von Fountas, A. | Lim, E. | Drake, W. | +23

CommentIn: J Clin Endocrinol Metab. 2020 May 1;105(5):. - PMID 31853553

5

Efficacy and safety of once-monthly pasireotide in Cushing's disease : a 12 month clinical trial

enthalten in: The lancet. Diabetes & endocrinology | 2018

von Lacroix, A. | Gu, F. | Gallardo, W. | +59

CommentIn: Lancet Diabetes Endocrinol. 2018 Jan;6(1):2-3. - PMID 29032080

6

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease : 12-month, Phase III pasireotide study

enthalten in: Endocrine | 2016

von Findling, J. | Fleseriu, M. | Newell-Price, J. | +5

7

Adrenal surgery in England : better outcomes in high-volume practices

enthalten in: Clinical endocrinology | 2016

von Palazzo, F. | Dickinson, A. | Phillips, B. | +5

8

Effectiveness of Metyrapone in Treating Cushing's Syndrome : A Retrospective Multicenter Study in 195 Patients

enthalten in: The Journal of clinical endocrinology and metabolism | 2015

von Daniel, E. | Aylwin, S. | Mustafa, O. | +25

9

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

enthalten in: Drug design, development and therapy | 2015

von Wolin, E. | Jarzab, B. | Eriksson, B. | +16

10

A 12-month phase 3 study of pasireotide in Cushing's disease

enthalten in: The New England journal of medicine | 2012

von Colao, A. | Petersenn, S. | Newell-Price, J. | +78

ErratumIn: N Engl J Med. 2012 Aug 23;367(8):780

1
[1]